HEPATOCYTE ASIALOGLYCOPROTEIN RECEPTOR ASSAY

描述（改编自研究者摘要）：大多数诊断 预测肝功能衰竭的技术只能从总体上解释， 肝功能，而不是特定结构的功能， 受体。通过使用获得的与肝功能相关的解剖信息 放射性和磁性胶体（MRI）已被证明是昂贵的， 相对无效。为了克服这些诊断局限性， 研究人员计划合成和表征含半乳糖的蛋白质 和用稳定同位素标记的纳米胶体。稳定同位素将是 通过中子活化分析定量。我们的非放射性，无毒 药物，通过以下方式针对肝细胞的去唾液酸糖蛋白受体 半乳糖，预计将迅速和特异性地从血液中去除 根据肝脏中功能性受体的数量。的动力学模拟 血液中这些物质的消耗可以估计功能性 肝脏中的受体受体靶向诊断剂与 稳定同位素标记和中子活化技术 新的和潜在的通用方法来设计的代理人，以衡量 肝脏和其他器官中的受体功能。最重要的是，稳定 同位素标记提供了测量多种受体活性的机会 同步 拟议商业应用：不可用

DESCRIPTION (Adapted from the Investigator's Abstract): Most diagnostic techniques to predict liver failure are interpretable only in terms of gross liver function, not in terms of the function of specific structures such as receptors. Anatomical information related to liver function obtained by using radioactive and magnetic colloids (MRI) has proven to be both costly and relatively ineffective. To overcome these diagnostic limitations, the investigators plan to synthesize and characterize galactose-containing proteins and nanocolloids labeled with stable isotopes. Stable isotopes will be quantitated by neutron activation analysis. Our non-radioactive, nontoxic agents, directed to the asialoglycoprotein receptor of hepatocytes by galactose, are expected to be rapidly and specifically removed from the blood based upon the number of functional receptors in the liver. Kinetic modeling of the depletion of these agents in blood can estimate the number of functioning receptors in the liver. Receptor-targeted diagnostic agents combined with stable isotope labeling and neutron activation represent a technologically novel and potentially general approach to the design of agents to measure receptor function in the liver and other organs. Most importantly, stable isotope labeling offers an opportunity to measure multiple receptor activities simultaneously. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE